NOVOCURE LTD (NVCR)

The stock moved closer to its 52-week high of $184.64, while remaining well above the 52-week low of $84.99. The reaction suggests investors viewed the quarter as a clear positive. The combination of a large earnings beat, strong revenue growth, and higher guidance outweighed concerns about ...

NVR's asset-light model and buybacks support long-term value, but falling earnings, weaker revenues and a premium valuation argue for patience.

NovoCure stock is coming off a very difficult five year stretch, with the share price down about 90%, yet the latest valuation checks still lean toward the shares looking cheap on several measures. That contrast, alongside fresh company developments in cancer therapies, is what investors are ...

NVE Corp president & CEO Baker sells $2.3m in shares

Navitas Semiconductor beats Q2 revenue estimates as AI-driven high-power demand and a stronger third-quarter outlook reinforce its growth strategy.